InnovoTEX Inc., a pre-clinical stage oncology therapeutics company, announced on Wednesday that it has named Tarak D Mody, PhD as its new director.
In the new role, Dr Mody is to use his extensive expertise in oncology business development, licensing and in forging strategic alliances with pharma and biotech organisations, to expedite development of the platform.
Dr Mody has served in the biopharmaceutical industry for several decades. Presently, he serves as chief business officer at the Parker Institute for Cancer Immunotherapy (PICI). He earlier worked as vice president of Business Development & Alliance Management at Five Prime Therapeutics. He has 20 years of experience at Pharmacyclics Inc. (now AbbVie, Inc.). He has served as a member of the original scientific team prior to transitioning into business development, where he was instrumental in the multi-asset acquisition from Celera Genomics, which included Bruton's tyrosine kinase (BTK) inhibitor discovery programs. He headed business development and intellectual property at Pharmacyclics.
OnCusp Therapeutics' CUSP06 receives US FDA Fast Track Designation
Telix Pharmaceuticals' Illuccix receives UK regulatory approval
MimiVax reports positive interim analysis of SurVaxM Phase 2b clinical trial
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
AbbVie and Xilio Therapeutics announce collaboration to develop tumour-activated immunotherapies
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Oxford BioDynamics announces distribution agreement with Regina Maria for EpiSwitch tests in Romania
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
Health Canada approves Merck's KEYTRUDA for resectable non-small cell lung cancer
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
NLS Pharmaceutics and Kadimastem plan multi-target approach to diabetes
Hoth Therapeutics and OnTargetx R&D partner on cancer research
CStone Pharmaceuticals' Cejemly included in ESMO NSCLC Living Guideline